FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021791122> ?p ?o ?g. }

• W2021791122 endingPage "8" @default.
• W2021791122 startingPage "1" @default.
• W2021791122 abstract "Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade gliomas (HGG) in phase II clinical trials. Patients and Methods. Data were collected from patients with recurrent HGG who initiated treatment with BEV outside a clinical trial protocol at two Belgian university hospitals. Results. 19 patients (11 M/8 F) were administered a total of 138 cycles of BEV (median 4, range 1-31). Tumor response assessment by MRI was available for 15 patients; 2 complete responses and 3 partial responses for an objective response rate of 26% for the intent to treat population were observed on gadolinium-enhanced T1-weighted images; significant regressions on T2/FLAIR were documented in 10 out of 15 patients (67%). A reduced uptake on PET was documented in 3 out of 4 evaluable patients. The six-month progression-free survival was 21% (95% CI 2.7-39.5). Two patients had an ongoing tumor response and remained free from progression after 12 months of BEV treatment. Conclusions. The activity and tolerability of BEV were comparable to results from previous prospective phase II trials. Reduced uptake on PET suggests a metabolic response in addition to an antiangiogenic effect in some cases with favorable clinical outcome." @default.
• W2021791122 created "2016-06-24" @default.
• W2021791122 creator A5017681768 @default.
• W2021791122 creator A5033042105 @default.
• W2021791122 creator A5039911802 @default.
• W2021791122 creator A5042310652 @default.
• W2021791122 creator A5062356516 @default.
• W2021791122 creator A5070241350 @default.
• W2021791122 creator A5076651121 @default.
• W2021791122 creator A5081718657 @default.
• W2021791122 creator A5082449165 @default.
• W2021791122 creator A5087777937 @default.
• W2021791122 creator A5091452189 @default.
• W2021791122 date "2012-01-01" @default.
• W2021791122 modified "2023-09-26" @default.
• W2021791122 title "An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals" @default.
• W2021791122 cites W1858161324 @default.
• W2021791122 cites W1959628099 @default.
• W2021791122 cites W1982080753 @default.
• W2021791122 cites W2001355942 @default.
• W2021791122 cites W2002727873 @default.
• W2021791122 cites W2013897414 @default.
• W2021791122 cites W2018101957 @default.
• W2021791122 cites W2025063591 @default.
• W2021791122 cites W2036044314 @default.
• W2021791122 cites W2046507292 @default.
• W2021791122 cites W2073477133 @default.
• W2021791122 cites W2075176584 @default.
• W2021791122 cites W2087990401 @default.
• W2021791122 cites W2093084676 @default.
• W2021791122 cites W2106234246 @default.
• W2021791122 cites W2117188579 @default.
• W2021791122 cites W2127745545 @default.
• W2021791122 cites W2132697290 @default.
• W2021791122 cites W2145835533 @default.
• W2021791122 cites W2149434165 @default.
• W2021791122 cites W2157769714 @default.
• W2021791122 cites W2157808018 @default.
• W2021791122 cites W2158681922 @default.
• W2021791122 cites W2162872529 @default.
• W2021791122 cites W2166921825 @default.
• W2021791122 cites W2167185669 @default.
• W2021791122 cites W2169590480 @default.
• W2021791122 cites W2170367762 @default.
• W2021791122 cites W2412946158 @default.
• W2021791122 cites W2624094894 @default.
• W2021791122 cites W4244177248 @default.
• W2021791122 cites W4255289481 @default.
• W2021791122 doi "https://doi.org/10.1155/2012/801306" @default.
• W2021791122 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3317219" @default.
• W2021791122 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22481934" @default.
• W2021791122 hasPublicationYear "2012" @default.
• W2021791122 type Work @default.
• W2021791122 sameAs 2021791122 @default.
• W2021791122 citedByCount "6" @default.
• W2021791122 countsByYear W20217911222012 @default.
• W2021791122 countsByYear W20217911222013 @default.
• W2021791122 countsByYear W20217911222015 @default.
• W2021791122 countsByYear W20217911222023 @default.
• W2021791122 crossrefType "journal-article" @default.
• W2021791122 hasAuthorship W2021791122A5017681768 @default.
• W2021791122 hasAuthorship W2021791122A5033042105 @default.
• W2021791122 hasAuthorship W2021791122A5039911802 @default.
• W2021791122 hasAuthorship W2021791122A5042310652 @default.
• W2021791122 hasAuthorship W2021791122A5062356516 @default.
• W2021791122 hasAuthorship W2021791122A5070241350 @default.
• W2021791122 hasAuthorship W2021791122A5076651121 @default.
• W2021791122 hasAuthorship W2021791122A5081718657 @default.
• W2021791122 hasAuthorship W2021791122A5082449165 @default.
• W2021791122 hasAuthorship W2021791122A5087777937 @default.
• W2021791122 hasAuthorship W2021791122A5091452189 @default.
• W2021791122 hasBestOaLocation W20217911221 @default.
• W2021791122 hasConcept C101070640 @default.
• W2021791122 hasConcept C126322002 @default.
• W2021791122 hasConcept C126838900 @default.
• W2021791122 hasConcept C143409427 @default.
• W2021791122 hasConcept C143998085 @default.
• W2021791122 hasConcept C197934379 @default.
• W2021791122 hasConcept C23131810 @default.
• W2021791122 hasConcept C2776694085 @default.
• W2021791122 hasConcept C2777802072 @default.
• W2021791122 hasConcept C2778227246 @default.
• W2021791122 hasConcept C2778375690 @default.
• W2021791122 hasConcept C2780739268 @default.
• W2021791122 hasConcept C2908647359 @default.
• W2021791122 hasConcept C31760486 @default.
• W2021791122 hasConcept C502942594 @default.
• W2021791122 hasConcept C535046627 @default.
• W2021791122 hasConcept C71924100 @default.
• W2021791122 hasConcept C99454951 @default.
• W2021791122 hasConceptScore W2021791122C101070640 @default.
• W2021791122 hasConceptScore W2021791122C126322002 @default.
• W2021791122 hasConceptScore W2021791122C126838900 @default.
• W2021791122 hasConceptScore W2021791122C143409427 @default.
• W2021791122 hasConceptScore W2021791122C143998085 @default.
• W2021791122 hasConceptScore W2021791122C197934379 @default.
• W2021791122 hasConceptScore W2021791122C23131810 @default.
• W2021791122 hasConceptScore W2021791122C2776694085 @default.

• next